AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)), AstraZeneca ((DE:ZEGA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca, in collaboration with Parexel, is conducting a Phase I clinical study titled A Phase I Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248. This study aims to evaluate the safety and tolerability of AZD4248 in healthy individuals and those with chronic kidney disease and type 2 diabetes, while also assessing the feasibility of home-based creatinine measurements.
The study involves testing AZD4248, administered both orally and via intravenous infusion, to determine its safety and effectiveness. It also includes a non-interventional component to evaluate home monitoring of creatinine levels in patients with diabetic kidney disease.
This randomized, single-blind study employs a sequential intervention model with a primary focus on treatment. Masking is double, involving both participants and care providers, to ensure unbiased results.
The study began on June 9, 2025, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on July 8, 2025, indicating ongoing recruitment.
For investors, this study could influence AstraZeneca’s stock performance, as positive outcomes may enhance the company’s portfolio in the diabetes and kidney disease sectors. This could also impact competitors in the pharmaceutical industry focusing on similar conditions.
The study is currently recruiting, with further details available on the ClinicalTrials portal.